Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy

Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy

INTRODUCTION: Current Italian guidelines recommend prophylaxis with granulocyte colony-stimulating factors (G-CSFs) to reduce the risk of chemotherapy-induced febrile neutropenia (FN). The availability of G-CSF biosimilars represents an opportunity for savings in the Italian National Healthcare Serv...

Full description

Bibliographic Details
Main Authors: Patrizia Berto, Marco Bellone, Alice Sabinot, Carmine Pinto, Massimo Martino, Daniele Generali, Pier Luigi Carriero, Maria Domenica Sanna
Format: Article
Language:English
Published: SEEd Medical Publishers 2022-02-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
biosimilars
budget impact analysis
cost saving
febrile neutropenia
granulocyte colony stimulating factor (g-csf)
Online Access:http://journals.seedmedicalpublishers.com/index.php/FE/article/view/1516

Internet

http://journals.seedmedicalpublishers.com/index.php/FE/article/view/1516

Similar Items